Victoria Atkinson

7.5k total citations
41 papers, 591 citations indexed

About

Victoria Atkinson is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Victoria Atkinson has authored 41 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 20 papers in Molecular Biology and 9 papers in Immunology. Recurrent topics in Victoria Atkinson's work include Cancer Immunotherapy and Biomarkers (20 papers), Melanoma and MAPK Pathways (20 papers) and CAR-T cell therapy research (18 papers). Victoria Atkinson is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), Melanoma and MAPK Pathways (20 papers) and CAR-T cell therapy research (18 papers). Victoria Atkinson collaborates with scholars based in Australia, United States and United Kingdom. Victoria Atkinson's co-authors include Georgina V. Long, Paolo A. Ascierto, Caroline Robert, Rahul Ladwa, Reinhard Dummer, James Larkin, Alexander M. Menzies, Vanna Chiarion‐Sileni, Mario Mandalà and Cheryl D. Coon and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Victoria Atkinson

40 papers receiving 578 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Victoria Atkinson Australia	13	480	270	181	109	47	41	591
Fareeda Hosein United States	4	472 1.0×	119 0.4×	190 1.0×	146 1.3×	39 0.8×	8	581
Candy Garcia United States	3	393 0.8×	81 0.3×	207 1.1×	101 0.9×	29 0.6×	3	484
Arielle L. Heeke United States	10	391 0.8×	240 0.9×	59 0.3×	117 1.1×	54 1.1×	31	554
Guy Ben‐Betzalel Israel	12	324 0.7×	104 0.4×	127 0.7×	62 0.6×	19 0.4×	24	398
Sang Hyung Lee South Korea	6	293 0.6×	96 0.4×	171 0.9×	78 0.7×	35 0.7×	7	441
M.T. Spiotto United States	3	521 1.1×	103 0.4×	429 2.4×	85 0.8×	30 0.6×	4	642
Zaida Morante Peru	11	266 0.6×	149 0.6×	113 0.6×	140 1.3×	40 0.9×	38	479
Lori A. Ehrlich United States	9	465 1.0×	302 1.1×	84 0.5×	28 0.3×	19 0.4×	20	707
Nancy Nixon Canada	10	233 0.5×	64 0.2×	85 0.5×	69 0.6×	15 0.3×	26	348
Nikita Patel United States	4	560 1.2×	72 0.3×	368 2.0×	133 1.2×	28 0.6×	10	667

Countries citing papers authored by Victoria Atkinson

Since Specialization

Citations

This map shows the geographic impact of Victoria Atkinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victoria Atkinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victoria Atkinson more than expected).

Fields of papers citing papers by Victoria Atkinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victoria Atkinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victoria Atkinson. The network helps show where Victoria Atkinson may publish in the future.

Co-authorship network of co-authors of Victoria Atkinson

This figure shows the co-authorship network connecting the top 25 collaborators of Victoria Atkinson. A scholar is included among the top collaborators of Victoria Atkinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victoria Atkinson. Victoria Atkinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhao, Frances, et al.. (2025). Comparative study of management strategies for immune checkpoint inhibitor‐induced inflammatory arthritis: rheumatologists versus oncologists. Internal Medicine Journal. 55(3). 426–434. 1 indexed citations

Long, Georgina V., Victoria Atkinson, Paolo A. Ascierto, et al.. (2024). A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).. Journal of Clinical Oncology. 42(16_suppl). TPS9602–TPS9602. 3 indexed citations

Weber, Jeffrey S., Muhammad Adnan Khattak, Matteo S. Carlino, et al.. (2024). Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.. Journal of Clinical Oncology. 42(17_suppl). LBA9512–LBA9512. 16 indexed citations

Khattak, Adnan, Jeffrey S. Weber, Tarek Meniawy, et al.. (2023). Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.. Journal of Clinical Oncology. 41(17_suppl). LBA9503–LBA9503. 50 indexed citations

Krause, Martín, Georgina V. Long, Victoria Atkinson, et al.. (2023). Case series: Immune checkpoint inhibitor-induced transverse myelitis. Frontiers in Neurology. 14. 1130313–1130313. 14 indexed citations

Burgess, Melinda, Colm Keane, Joshua W.D. Tobin, et al.. (2022). Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia. Acta Haematologica. 146(2). 166–171. 1 indexed citations

Atkinson, Victoria, Shahneen Sandhu, Geke A.P. Hospers, et al.. (2020). Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research. 30(3). 261–267. 25 indexed citations

Carlino, Matteo S., Alexander M. Menzies, Victoria Atkinson, et al.. (2020). Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clinical Cancer Research. 26(19). 5086–5091. 30 indexed citations

Agarwala, Sanjiv S., Merrick I. Ross, Jonathan S. Zager, et al.. (2020). 1125P A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Results in patients naïve to immune checkpoint blockade. Annals of Oncology. 31. S756–S756. 3 indexed citations

10.

Gebhardt, Christoffer, Paolo A. Ascierto, Victoria Atkinson, et al.. (2020). The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. European Journal of Cancer. 138. 68–76. 12 indexed citations

11.

Arance, Ana, Steven O’Day, Luis de la Cruz‐Merino, et al.. (2020). LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004. Annals of Oncology. 31. S1173–S1173. 19 indexed citations

12.

Atkinson, Victoria, Georgina V. Long, Matteo S. Carlino, et al.. (2020). Activity and safety of third-line BRAF-targeted therapy (TT) following first-line TT and second-line immunotherapy (IT) in advanced melanoma.. Journal of Clinical Oncology. 38(15_suppl). 10049–10049. 3 indexed citations

13.

Zager, Jonathan S., Amod Sarnaik, Shari Pilon‐Thomas, et al.. (2020). 1123P A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Initial results in patients refractory to checkpoint blockade. Annals of Oncology. 31. S755–S756. 4 indexed citations

14.

Dummer, Reinhard, Jan C. Brase, James E. Garrett, et al.. (2020). Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. The Lancet Oncology. 21(3). 358–372. 85 indexed citations

15.

Mandalà, Mario, M. Del Vecchio, Helen Gogas, et al.. (2018). Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238). British Journal of Cancer. 119(11). 41–42. 1 indexed citations

16.

Visser, Els, David Edholm, B. Mark Smithers, et al.. (2018). Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. Journal of Surgical Oncology. 117(8). 1687–1696. 21 indexed citations

17.

Ladwa, Rahul, Vladimir Andelkovic, & Victoria Atkinson. (2016). Pembrolizumab for Metastatic Melanoma: Results of the Complete Responders On the Named Patient Access Program. Asia-Pacific Journal of Clinical Oncology. 12. 48–48. 1 indexed citations

18.

Long, Georgina V., Victoria Atkinson, Paolo A. Ascierto, et al.. (2016). Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. Annals of Oncology. 27(10). 1940–1946. 89 indexed citations

19.

McArthur, Grant A., James Larkin, Brigitte Dréno, et al.. (2015). 25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study. European Journal of Cancer. 51. S722–S723. 7 indexed citations

20.

Atkinson, Victoria, et al.. (2011). Case 1: Fever and a genital ulcer in a recent immigrant. Paediatrics & Child Health. 16(2). 75–76. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact